Therefore, CTSC inhibitors have been developed for the treatment of non-cystic fibrosis bronchiectasis (NCFBE), chronic obstructive pulmonary disease (COPD), rheumatoid arthritis (RA), inflammatory bowel disease (IBD), and anti-neutrophil cytoplasmic antibody-associated vasculitis [10,11,12]. Here, CTSC is linked to inflammatory bowel disease.